Though some studies of NSCLC patients with MET alterations have shown modest response to ICI therapy, a recent analysis found MET amplified tumors, but not those with MET exon 14 skipping mutations, had significantly improved overall survival compared to chemotherapy when given ICI after progression on first-line chemotherapy (56). This evidence concerns the gene MET and non-small cell lung carcinoma.